Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.

Authors:
Chan PLS; Singh RSP; Cox DS; Shi H; Damle B and 1 more

Journal:
CPT Pharmacometrics Syst Pharmacol

Publication Year: 2023

DOI:
10.1002/psp4.13039

PMCID:
PMC10725264

PMID:
37803876

View on PubMed View on PMC View Publisher
Journal Information

Full Title: CPT Pharmacometrics Syst Pharmacol

Abbreviation: CPT Pharmacometrics Syst Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediat…
Caleffi-Marchesini ER; Herling AA; Macente J and 8 more (2023) - Transparency Score: 3/6
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progre…
Knöchel J; Bergenholm L; Ibrahim E and 7 more (2023) - Transparency Score: 3/6
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.
Sokolov V; Yakovleva T; Stolbov L and 4 more (2023) - Transparency Score: 3/6
A "middle-out approach" for the prediction of human drug disposition from preclinical data using si…
Yau E; Gertz M; Ogungbenro K and 2 more (2023) - Transparency Score: 3/6
A model-based approach leveraging in vitro data to support dose selection from the outset: A framew…
Sánchez J; Claus C; Albrecht R and 8 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the nonmem model is included in data s1 .; the model was then modified with the use of a power model for the nclcr effect on cl normalized to the estimated breakpoint below the estimated breakpoint of 70 ml/min/1 73 m 2 and a power function for dose effect on f1 (data s1 ) normalized to 300 mg based on substantial reductions in ofv observed in association with these modifications.; data s1 click here for additional data file."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT All authors are employees of Pfizer and may hold stock or stock options."

Evidence found in paper:

"FUNDING INFORMATION This work was funded by Pfizer Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025